BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas.
Sign Up to like & getrecommendations! Published in 2021 at "Neuro-oncology"
DOI: 10.1093/neuonc/noab154
Abstract: BACKGROUND Gliomas comprise the most common type of primary brain tumor, are highly invasive, and often fatal. IDH-mutated gliomas are particularly challenging to image and there is currently no clinically accepted method for identifying the… read more here.
Keywords: mutated gliomas; bold asynchrony; tumor burden; idh mutated ... See more keywords
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-070071
Abstract: Introduction The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and holds… read more here.
Keywords: mutated diffuse; idh mutated; therapy; quality life ... See more keywords
Abstract 3870: The addition of CB-839 to temozolomide significantly reduces glioma aspartate and glutamate in an IDH mutated patient derived glioma xenograft model
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-3870
Abstract: Background: IDH mutated gliomas are critically dependent on glutaminase for glutamate biosynthesis. CB-839 is a novel glutaminase-1 inhibitor which has demonstrated efficacy in both genetically engineered and patient derived IDH mutated glioma cells, especially in… read more here.
Keywords: glutamate; glioma; idh mutated; model ... See more keywords
Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma
Sign Up to like & getrecommendations! Published in 2021 at "In Vivo"
DOI: 10.21873/invivo.12332
Abstract: Background/Aim: The application of Oncomine Comprehensive Assay v3 (OCAv3) panel in diffuse gliomas (DGs) remains unknown. We investigated the utility of OCAv3-based next-generation sequencing (NGS) in isocitrate dehydrogenase (IDH)-mutated grade II-III DGs. Patients and Methods:… read more here.
Keywords: grade iii; comprehensive assay; mutated grade; idh mutated ... See more keywords
Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15041042
Abstract: Simple Summary In the present review, we reported the main findings describing tumor-associated microenvironment in patients with IDH mutated and wild-type gliomas. We also focused on the main differences between microenvironment composition reporting data about… read more here.
Keywords: microenvironment; idh mutated; tumor microenvironment; gliomas ... See more keywords